公开(公告)号：EP0739903A4

公开(公告)日：1998-07-08

申请号：EP95907849

申请日：1995-02-07

申请人： SHIONOGI & CO

发明人： HAGISHITA SANJI ,  KAMATA SUSUMU ,  MURAKAMI YASUSHI ,  HAGA NOBUHIRO ,  ISHIHARA YASUNOBU ,  KONOIKE TOSHIRO

IPC分类号： A61K31/17 ,  A61K38/00 ,  A61K38/05 ,  A61P1/04 ,  C07C275/28 ,  C07K5/06 ,  C07K5/062

CPC分类号： C07K5/0606 ,  A61K38/00 ,  C07C275/28 ,  C07K5/06026 ,  C07K5/06139

摘要： A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, having a strong affinity for gastrin receptors and/or CCK-B receptors but not for CCK-A receptors and hence being useful for curing diseases related to gastrin receptors and/or CCK-B receptors without inducing side effect related to CCK-A receptors, wherein R1 represents hydrogen or lower alkyl; R2 represents lower alkoxy, lower alkylamino, lower cycloalkyl, optionally substituted phenyl or optionally substituted heterocycle; R3 represents optionally substituted phenyl; and R4 represents optionally substituted phenyl, optionally substituted cycloalkyl, optionally substituted alkyl or optionally substituted heterocycle.

摘要翻译： 由通式（I）表示的化合物或其药学上可接受的盐对胃泌素受体和/或CCK-B受体具有强亲和力，但对CCK-A受体不具有强亲和力，因此可用于治疗与胃泌素受体和/ 或CCK-B受体而不诱导与CCK-A受体有关的副作用，其中R1代表氢或低级烷基; R2代表低级烷氧基，低级烷基氨基，低级环烷基，任选取代的苯基或任选取代的杂环; R3代表任选取代的苯基; 并且R4代表任选取代的苯基，任选取代的环烷基，任选取代的烷基或任选取代的杂环。

公开(公告)号：EP0728748A4

公开(公告)日：1997-03-19

申请号：EP95902983

申请日：1994-12-19

申请人： SHIONOGI & CO

发明人： HAGISHITA SANJI ,  KAMATA SUSUMU ,  SENO KAORU ,  HAGA NOBUHIRO ,  ISHIHARA YASUNOBU

IPC分类号： C07D243/12 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/14 ,  A61K31/55

CPC分类号： C07D403/12 ,  C07D243/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/14

摘要： A benzodiazepine derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof, wherein R1 represents a single bond, -CH2-, -CH2O-, -OCH2-, -SCH2- or (a); R2 represents lower alkyl, -COOR5, -CONH(CH2)nCOOR5, -CONHSO2R5, -SO2NHCOR5 or optionally substituted heterocyclic group, (wherein R5 represents hydrogen, lower alkyl or benzyl; and n represents an integer of 1 to 5); R3 represents a single bond, -CO- or -CONH; and R4 represents optionally substituted heterocylic group, optionally substituted lower alkyl, optionally substituted lower cycloalkyl, optionally substituted aryl, or lower alkoxycarbonyl. This compound has a high affinity for gastrin receptors and/or CCK-B receptors but not for CCK-A receptors, so that it is useful for curing diseases associated with gastrin receptors and/or CCK-B receptors without inducing the side effects associated with CCK-A receptors.